



Lina Machtoub | Yu Kasugai

# AMYOTROPHIC LATERAL SCLEROSIS

Advances and Perspectives of Neuronanomedicine







---

AMYOTROPHIC

---

LATERAL SCLEROSIS

---





# AMYOTROPHIC LATERAL SCLEROSIS

*Advances and Perspectives of Neuronanomedicine*

Lina Machtoub  
Yu Kasugai

CRC Press  
Taylor & Francis Group  
6000 Broken Sound Parkway NW, Suite 300  
Boca Raton, FL 33487-2742

© 2016 by Taylor & Francis Group, LLC  
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works  
Version Date: 20151110

International Standard Book Number-13: 978-981-4463-05-8 (eBook - PDF)

This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access [www.copyright.com](http://www.copyright.com) (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

**Trademark Notice:** Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

**Visit the Taylor & Francis Web site at**  
**<http://www.taylorandfrancis.com>**

**and the CRC Press Web site at**  
**<http://www.crcpress.com>**

# Contents

*Preface*

vii

<b>1 Clinical Features of Amyotrophic Lateral Sclerosis</b>	<b>1</b>
1.1 What Is Amyotrophic Lateral Sclerosis?	1
1.2 ALS Signs and Symptoms	3
1.3 The Different Types of ALS	6
1.3.1 Familial ALS (Hereditary)	7
1.3.2 Familial ALS: Signs and Symptoms	13
1.3.3 How to Manage Familial ALS?	14
1.3.4 Sporadic ALS (Acquired)	14
1.3.5 Sporadic ALS: Signs and Symptoms	15
1.4 ALS: Clinical Case Studies	19
<b>2. Environmental Factors</b>	<b>25</b>
2.1 What Environmental Factors Are Suspect in ALS?	25
2.2 Toxic Metals and Solvents	27
2.3 The Possible Effects of Exercise or Pesticides	28
2.4 Environmental Influences of Viruses	28
2.5 BMAA Neurotoxic Effects	29
2.6 Are Toxins in Seafood Causing ALS?	30
<b>3 Diagnostic Criteria of Amyotrophic Lateral Sclerosis</b>	<b>35</b>
3.1 Steps in the Diagnosis of ALS	35
3.1.1 History and Physical Exam	37
3.1.2 Electrophysiology Studies	37
3.1.3 Radiology Studies	41
3.2 Electrophysiology in the Revised EEC	47
3.3 Nerve Conduction Studies	47
3.4 Clinical Features in the Diagnosis of ALS	48

3.5	Inconsistent Clinical Features	50
3.6	ALS Electrophysiological Features	51
3.7	ALS Neuroimaging Features	55
<b>4</b>	<b>Perspectives of Neuronanomedicine</b>	<b>59</b>
4.1	Nanomedicine and Neurological Disorders	59
4.2	CNS Neuroprotective Potentials	64
4.3	Nanocarriers and CNS-Targeted Drug Delivery	68
4.4	Applications Based on Cell-Mediated Drug Delivery	77
4.5	CNS Nano-Based Diagnostic Approaches	80
4.5.1	Proposed in vitro Nanodiagnostic Approaches	83
4.5.2	Proposed in vivo Nanodiagnostic Approaches	84
4.5.2.1	Nano-based optical imaging	86
4.5.2.2	SECARS microscopy	87
4.6	Inflammation and Neurodegeneration: Can We Measure Neuroprotection and Repair through Imaging Techniques?	88
4.7	Constraints in the Treatment of Neurodegenerative Diseases: Future Directions	91
<b>5</b>	<b>Novel Therapeutic Approaches</b>	<b>99</b>
5.1	Conventional Treatments for ALS	99
5.2	Occupational Therapy and Supportive Therapy	100
5.3	Cell Replacement Therapy and Future Challenges	102
5.4	Stem Cell Transplantation Therapy	113
5.5	Clinical Applications of Cell Transplant Therapy	116
5.6	Trials of Other Cell Sources for Stem Cell Therapy	119
5.7	Stem Cell Therapy: Clinical Trials	122
5.8	Induced Pluripotent Stem (iPS) Cell Therapy	124
5.9	Gene Therapy and Future Challenges	127
	<i>List of Abbreviations</i>	143

# Preface

Amyotrophic lateral sclerosis (ALS) is one of the most devastating motor system neurodegenerative diseases, causing around 10,000 deaths each year. The neuropathology of ALS, which leads to muscle weakness, is mostly confined to motor neurons in the cerebral cortex, motor nuclei of the brainstem, and anterior horns of the spinal cord.

The major goal in treating ALS, currently, is to recognize the onset of the disease early in order to initiate appropriate therapy and delay functional and cognitive losses. Upon the discovery of mutated SOD1 in ALS, many hypotheses have been proposed on how mutant SOD1 could cause neurodegeneration, including aberrant redox chemistry, mitochondrial damage, excitotoxicity, microglial activation and inflammation, as well as SOD1 aggregation. Recently, the implication of biocompatible nanotechnologies set the stage for an evolutionary leap in diagnostic imaging and therapy. In this scope, the book provides a comprehensive overview of the hypotheses and the molecular mechanisms associated with the inflammatory processes in motor neuron disorders and presents the latest research studies on ALS, highlighting the recent findings using newly developed imaging modalities and the innovative approaches of highly sensitive molecular imaging. In addition, by using recently developed surface-enhanced nanoimaging microscopy, the book offers new perspectives on neuroimaging and insights into early diagnosis and promising therapeutic strategies.

**Lina Machtoub and Yu Kasugai**

Universitätsklinik für Radiodiagnostik

Medizinische Universität Innsbruck

Anichstr.35, 6020 Innsbruck, Austria

May 2015



## **Chapter 1**

# **Clinical Features of Amyotrophic Lateral Sclerosis**

The aim of this chapter is to introduce some basic concepts about amyotrophic lateral sclerosis (ALS). We start by outlining the concepts of motor neuron diseases and the clinical features of ALS, and present some recent clinical case studies. This will act as a basis to understand the subsequent chapters.

### **1.1 What Is Amyotrophic Lateral Sclerosis?**

Motor neuron disease, interchangeably known as amyotrophic lateral sclerosis (ALS), is a neurodegenerative disorder characterized by a progressive muscular paralysis reflecting degeneration of motor neurons in the primary motor cortex, brain stem, and spinal cord. The disease mainly affects patients between 50 and 70 years of age. ALS was originally described by the French physician Jean-Martin Charcot in the 1870s (Fig. 1.1). ALS is widely known as Lou Gehrig's disease, named after the famous baseball player Lou Gehrig, who died of ALS, and which confines star British physicist Stephen Hawking to the wheelchair (Fig. 1.2). ALS is universally fatal, with an average mortality of 5 years after onset.





**Figure 1.1** Dr. Jean-Martin Charcot, who first described ALS in a publication in Paris (1869).

The phenotypic expression of ALS is highly heterogeneous and determined by four elements: (1) body region of onset, (2) relative mix of upper motor neuron (UMN) and lower motor neuron (LMN) involvement, (3) rate of progression, and (4) cognitive impairment. ALS causes progressive weakness, which may at first be mild and subtle, but becomes severe and eventually affects the breathing muscle machinery. This disease ultimately results in death. The onset of the disease is insidious, and symptoms may be disregarded by the patient for several weeks or months. The first physicians consulted are usually general practitioners, orthopedic surgeons, or rheumatologists and only rarely neurologists. Even in countries with well-developed healthcare systems, it takes a year on average before the diagnosis is made. Up to now the diagnosis of ALS is still a clinical one and electromyography (EMG) is the most important technical test to support the diagnosis. Laboratory tests



**Figure 1.2** Notable people affected with ALS: (left) Lou Gehrig, Stephen Hawking, and (right) Jon Stone.

and imaging, including MRI, do not yield diagnostically positive results, but are necessary to exclude other potentially better treatable diseases.

## 1.2 ALS Signs and Symptoms


The first symptoms of ALS may be so subtle that they are overlooked: like muscle twitching, cramping, stiffness, weakness, involuntary jerking movements, tremors, inability to control the bowels or the bladder, or inability to move or open the eyes completely. As the weakness in the limb muscles progresses, muscle tissue is lost (atrophy), and the arms and legs begin to look thinner. Speech may become slurred, and later chewing and swallowing become difficult. Individuals with this disorder lose their strength, the ability to walk, and use of their hands and arms. Breathing becomes difficult because the muscles of the respiratory system weaken. Most people with ALS die from respiratory failure (Fig. 1.3).

There have been numerous debates on whether the upper or the lower motor neuron is first affected by the disease process. Upper motor neuron signs are preserved or exaggerated tendon reflexes in the presence of muscle atrophy and weakness. The muscle tone may be increased corresponding to spasticity more in the lower than



**Figure 1.3** The hallmark of ALS is muscle denervation and wasting. Noninvasive ventilation of a patient with ALS. Photos courtesy of Robert Brown, MD, Harvard Medical School, Massachusetts General Hospital. V. McGuire et al., *Neurology* 1996;47: 571–573.

the upper extremities. In about 30% of the cases a Babinski sign may be observed. Signs of corticobulbar involvement are increased masseter reflexes, pathological laughing, crying, and yawning, which are also called pseudobulbar affect. The manifestation of upper and lower motor neuron features usually begins focally and progresses to involve contiguous regions of the body with decreasing severity. Approximately two-thirds of cases start in the limbs and one-third in the bulbar group of muscles; only a very small percentage of them begin with respiratory muscle involvement. Many patients, however, do not show signs of the upper motor neuron in early stages of the disease. Signs of the lower motor neuron are muscle atrophy, weakness, and fasciculations. In early stages of the disease, patients frequently speak of clumsiness and not so often of weakness. The onset of ALS is usually focal and asymmetrical: in somewhat more than 30% of the cases in the upper extremities, in about one-third in the lower extremities, and in about 25% in the bulbar region. A special phenotype is the so-called flail arm syndrome with onset of muscle weakness in the proximal upper extremities, while the legs may be spared for a long time. The flail leg syndrome with onset of the symptoms in the proximal lower extremities is observed less



**Figure 1.4** Lesions of both first and second motor neurons: paresis, muscular atrophy fasciculation, emotional lability, spastic paraparesis, tongue muscle atrophy, dysarthria, dysphagia.

frequently. These two phenotypes are characterized by an overall better prognosis, i.e., longer survival. Another special phenotype is progressive bulbar palsy. A distinction between pseudobulbar and bulbar involvement may be difficult, and the leading clinical signs are dysarthria and dysphonia in conjunction with dysphagia, atrophy, fasciculations of the tongue, and sialorrhea (Fig. 1.4). These patients frequently also show pseudobulbar affect. Survival is shorter than that of patients with disease onset in the extremities. Signs of an involvement of the autonomic nerve system, such as reduced perfusion of the extremities, decrease in the heart frequency variability, or changes detected in the electrocardiogram, can be observed. Sensory disturbances and pain are not typical for

ALS, although they have been described. Relevant sensory deficits raise doubts concerning the diagnosis. Respiratory insufficiency develops in the late stages of the disease and is a hallmark of the terminal phase. Loss of body weight frequently occurs early in the disease and may be caused by muscle wasting, dysphagia, and hypermetabolism. Very recently, an association between ALS and frontotemporal dementia has been increasingly discussed. While many patients show mild frontal signs, about 25% may manifest frontotemporal dementia. Depression may develop during the course of the disease and may, at least in some patients, become a relevant clinical aspect. It is not clear whether primary lateral sclerosis (PLS), a disease with selective upper motor neuron signs, is a variant of ALS or a distinct disease. A considerable portion of these patients, however, develop signs of the lower motor neuron over years. Progressive muscular atrophy (PMA) is characterized by pure lower motor neuron signs and otherwise resembles ALS. It has been suggested to regard PMA as a variant of ALS.

### **1.3 The Different Types of ALS**

The different types of ALS have different causes. In approximately 5%–10% of patients, the disease is inherited; 20% of these individuals have a mutation of the SOD1 gene, approximately 2%–5% of the TARDBP (TDP-43) gene, and 2%–4% of the FUS/TLS gene. Most patients with ALS, however, have no obvious family history and have sporadic ALS. To date, the only specific marker of sporadic ALS is the presence of inclusions staining positively for ubiquitin and TDP-43 in degenerating motor neurons.

The genetic basis of ALS continues to be investigated (Fig. 1.5). Recently, mutations in the TTP-43 gene have been found to be a cause of some forms of ALS. Mutations in genes often encode proteins that function improperly. Mutations in TTP-43 form proteins that do not properly modify RNA (ribonucleic acid) in motor neurons. This is thought to contribute to the disease process. Identifying the genes and their abnormal protein products helps identify the targets for treatment.